← all works
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Post-publication record
- Nature
- Retraction
- Reason
- Duplication of/in Article;
- Date
- 11/1/2011 0:00
- Flagged by OpenAlex?
- Yes
Source: Retraction Watch, joined by DOI. OpenAlex records retraction as is_retracted, a boolean over a state space with at least four values, so it cannot express an expression of concern, a correction or a reinstatement — it reports them as false, which reads as “fine”.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- Annals of Oncology
- Topic
- Bladder and Urothelial Cancer Treatments
- Field
- Medicine
- Canadian institutions
- Princess Margaret Cancer Centre
- Funders
- Eli Lilly and Company
- Keywords
- MedicineVinblastineGemcitabineInternal medicineOncologyHazard ratioBladder cancerCisplatinTransitional cell carcinomaProgression-free survivalChemotherapyUrologyConfidence intervalCancer
- Has abstract in OpenAlex
- no